Moving the Needle Forward in Cancer Rehabilitation

Commentary
Video

It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.

When looking towards the future, Jessica Cheng, MD, hopes that patients and clinicians will underscore the importance of adding cancer rehabilitation into treatment plans as the field becomes more widespread.

She noted that with the implementation of cancer rehabilitation into treatment strategies, performance status and function can be significantly improved, which may correlate with better outcomes and reduced hospital stays. Cheng, assistant clinical professor in the Department of Supportive Care Medicine at City of Hope, wants the word to spread about this niche area, as it may allow for more informed treatment decisions and serve as an “integral part of the cancer space”.

With her catchphrase of “prehab for all”, she hopes that colleagues will learn more about cancer rehabilitation and what it can mean for their patients. By developing a greater understanding of cancer rehabilitation, practices may help patients navigate their treatment course more easily while aiding their recovery following therapy.


Transcript:

I see the value of rehabilitation medicine in the cancer space as an integral part of the cancer space. My heart’s desire is that every institution that takes care of patients with cancer will recognize the importance of optimizing function and performance status from the beginning and throughout the cancer journey from prehabilitation to rehabilitation. There’s a lot of room for growth there.

My catchphrase recently is “prehab for all”. I want everyone to be armed with this knowledge of what they can do that’s in their control to optimize their abilities for meaningful activities throughout the cancer journey. I hope that oncologists and rehabilitation physicians alike will see that there’s an opportunity with cancer prehabilitation to enable [patients] to get their cancer treatment, get through it better, and recover better. That’s my hope: that this will just spread even more like wildfire than it already is.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Related Content